

ReValving™: next-generation cath lab therapy for interventional cardiology, to be showcased in Boston

by Ronald C. Trahan


CoreValve, S.A., has developed a universal delivery system for percutaneously replacing a heart valve—based on a catheter delivery system and a breakthrough *self-expanding-stent approach* on a beating heart—that avoids open-heart surgery. **ReValving™** can be adapted to any biological valve currently marketed and synthetic valves when approved, initially in the aortic position (but also, in the future, in the mitral position)—allowing CoreValve’s procedure to be completed in a “cath lab” just like angioplasty and stenting.

“There is a significant unmet medical need for heart valve replacement that is due only to the heart valve replacement procedure itself, which has historically required open-heart surgery,” says world-renowned interventional cardiologist Eberhard Grube, M.D., Chief of Cardiology and Angiology at The Heart Center Siegburg, Siegburg, Germany, and a Consulting Professor at Stanford University’s School of Medicine, who was the first to use the CoreValve ReValving™ system in a human, in the summer of 2004. “I believe the CoreValve approach will, over time, revolutionize heart valve replacement and finally fulfill the great promise of being able to non-surgically replace an aortic heart valve.”

The aortic valve is shaped in the manner of a closed tulip, with three ‘leaflets’ that open and shut with each beat of the heart. With age, leaflets can calcify and become extremely difficult to open. Eventually, patients with *aortic stenosis* require open-heart surgery to replace the faulty valve.

“ReValving—implanting a new valve over the defective valve *percutaneously*—redefines the way valve replacement is performed, changing it from very complex and invasive surgery to a relatively simple procedure that avoids opening the chest,” says CEO Jacques Séguin, M.D., Ph.D., the cardiovascular surgeon who co-founded CoreValve and previously founded Devax. “We are extremely proud to have been selected by Medtech Insight to present the CoreValve story to corporate and other select investors at the upcoming In³ conference in Boston, in October.”

Caution: Investigational Device. Limited by Federal (USA) Law to Investigational Use Only.



Investment In Innovation (In³): A Preview of Early-Stage Medical Technology Companies The Westin Copley Place Hotel, Boston, Massachusetts, October 21-22, 2004

Medtech Insight’s In³ conferences have drawn a total of more than 3,300 senior execs from the investment community and major medtech companies, and have featured more than 410 innovative early-stage presenting companies. In³ Boston will, once again, feature a new group of over 50 early-stage medical technology companies seeking partnering and/or investment.

To register for this conference, please call 949-219-0150 or 888-290-2225 (toll-free in the U.S.), send an email to in3@medtechinsight.com, or register online at www.medtechinsight.com.

What other emerging-company CEOs are saying about Medtech Insight’s In³ events:

“The Boston conference in October will be our second Medtech Insight conference to date. Our first experience—at the Medtech Insight conference held in San Francisco in June—was a very positive one, in which we were able to receive the focused attention of key active investors and business development execs.”

Eric K. Mangiardi
President and CEO
Alveolus
Charlotte, North Carolina

“We presented our story at a Medtech Insight conference in October 2001, where we began dialogues with VCs. We got our first term sheet the following spring and series ‘A’ funding shortly thereafter. There’s no doubt Medtech Insight helped us then, so we’re presenting again, in Boston, as we organize our series ‘B’ funding.”

Larry Blankenship
President and CEO
Cardio-Optics
Boulder, Colorado

“Medtech Insight’s conferences have plugged a huge hole for private and corporate investors by orchestrating exceptional opportunities for emerging companies to get noticed. This is a fantastic chance for our company to appraise an extensive number of potential suitors at just a single event.”

Dr. Said Jahanmir
President and CEO
MITIHeart
Gaithersburg, Maryland

Ronald C. Trahan is President/CEO of Ronald Trahan Associates Inc. (www.ronaldtrahan.com), a public relations/investor relations firm that serves big and small companies, both public and private.